Systemic vasculitis developed after immune checkpoint inhibition: Comment on the article by Cappelli et al

OnderzoeksoutputAcademicpeer review

4 Citaten (Scopus)


With much interest, we read the recent systematic review on rheumatic and musculoskeletal immune-related adverse events (IRAEs) due to immune checkpoint inhibitors by Cappelli et al1 . The mechanistic basis on which the immune checkpoint inhibitors cause immune-related adverse events, dictates that basically any autoimmune disease could occur at an increased frequency in any of the patients treated with these agents. We think there is an underestimation of autoimmune disease development in these patients due to patient underreporting and physician unfamiliarity.

Originele taal-2English
Pagina's (van-tot)1275
Aantal pagina's1
TijdschriftArthritis Care and Research
Nummer van het tijdschrift8
StatusPublished - aug-2018

Citeer dit